Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Morgan Stanley Sticks to Its Buy Rating for Tenet Healthcare (THC)

Tipranks - Tipranks - Sat May 2, 9:00AM CDT

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Tenet Healthcare, with a price target of $254.00.

Claim 55% Off TipRanks

According to TipRanks, Hettenbach is ranked #3161 out of 12160 analysts.

Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $254.08.

See the top stocks recommended by analysts >>

Based on Tenet Healthcare’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.37 billion and a net profit of $906 million. In comparison, last year the company earned a revenue of $5.22 billion and had a net profit of $406 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in March 2026, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.

Read More on THC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).